GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchard Therapeutics PLC (STU:OT10) » Definitions » Float Percentage Of Total Shares Outstanding

Orchard Therapeutics (STU:OT10) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 19, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Orchard Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Orchard Therapeutics's float shares is 0.00 Mil. Orchard Therapeutics's total shares outstanding is 22.76 Mil. Orchard Therapeutics's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Orchard Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Orchard Therapeutics's Institutional Ownership is 8.60%.

Orchard Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Orchard Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/22.76
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchard Therapeutics (STU:OT10) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchard Therapeutics PLC (STU:OT10) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
OCS GNLX CGEM ORIC IMNM RNA ALXO MRNS CDMO ITOS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ORTX:USA OT10:Germany
Address
245 Hammersmith Road, London, GBR, W6 8PW
Website
https://www.orchard-tx.com
Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.

Orchard Therapeutics (STU:OT10) Headlines

No Headlines